Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines.

Dillman, Robert O; Nistor, Gabriel I; McLelland, Bryce T; Hsieh, Candace; Poole, Aleksandra J; Cornforth, Andrew N; Keirstead, Hans S

Dillman, Robert O; Nistor, Gabriel I; McLelland, Bryce T; Hsieh, Candace; Poole, Aleksandra J; Cornforth, Andrew N; Keirstead, Hans S.

Afiliação

Dillman RO; AIVITA Biomedical, Inc. Irvine, CA 92612, USA.
Nistor GI; Hoag Cancer Institute, Newport Beach, CA 92663, USA.
McLelland BT; AIVITA Biomedical, Inc. Irvine, CA 92612, USA.
Hsieh C; AIVITA Biomedical, Inc. Irvine, CA 92612, USA.
Poole AJ; AIVITA Biomedical, Inc. Irvine, CA 92612, USA.
Cornforth AN; AIVITA Biomedical, Inc. Irvine, CA 92612, USA.
Keirstead HS; Hoag Cancer Institute, Newport Beach, CA 92663, USA.

Oncotarget ; 10(51): 5359-5371, 2019 Sep 03.

Article em En | MEDLINE | ID: mdl-31523394

Palavras-chave

dendritic cell vaccines; metastatic melanoma; programmed cell death protein -1 (PD-1)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google